{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:53:05Z","timestamp":1768805585309,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.canrad.2024.10.002","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:58:18Z","timestamp":1732298298000},"page":"719-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Transformative clinical trials in gynaecologic radiation oncology in 2023\u20132024: Shaping modern treatment practices"],"prefix":"10.1016","volume":"28","author":[{"given":"Zineb","family":"El Ayachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Gabro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Camprodon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Maingon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2024.10.002_bib0180","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1200\/JCO.22.02852","article-title":"Randomized phase III study comparing neoadjuvant chemotherapy followed by surgery versus chemoradiation in stage IB2-IIB cervical cancer: EORTC-55994","volume":"41","author":"Kenter","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0185","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1200\/JCO.2017.75.9985","article-title":"Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial","volume":"36","author":"Gupta","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0190","doi-asserted-by":"crossref","first-page":"109682","DOI":"10.1016\/j.radonc.2023.109682","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer\u00a0\u2013\u00a0Update 2023","volume":"184","author":"Cibula","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0195","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"P\u00f6tter","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.radonc.2022.02.038","article-title":"Point-A vs. volume-based brachytherapy for the treatment of cervix cancer: a meta-analysis","volume":"170","author":"Hande","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0205","doi-asserted-by":"crossref","first-page":"109589","DOI":"10.1016\/j.radonc.2023.109589","article-title":"ESGO\/ESTRO quality indicators for radiation therapy of cervical cancer","volume":"183","author":"Chargari","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0210","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.canrad.2024.10.002_bib0215","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.canrad.2024.10.002_bib0220","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0225","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.10.002_bib0235","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0240","doi-asserted-by":"crossref","first-page":"103638","DOI":"10.1016\/j.critrevonc.2022.103638","article-title":"A systematic review and meta-analysis of adjuvant chemotherapy after chemoradiation for locally advanced cervical cancer","volume":"172","author":"Horeweg","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0230","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ygyno.2024.07.019","article-title":"Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: a randomized, double-blind, phase III ENGOT-cx11\/GOG-3047\/KEYNOTE-A18 study","volume":"190","author":"Duska","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0245","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","article-title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial","volume":"404","author":"McCormack","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.10.002_bib351","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005572","article-title":"Are we making progress in curing advanced cervical cancer-again?","author":"Lindegaard","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.canrad.2024.10.002_bib0250","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1200\/JCO.20.02530","article-title":"Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer (PARCER): a randomized controlled trial","volume":"39","author":"Chopra","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0255","doi-asserted-by":"crossref","first-page":"e2300478","DOI":"10.1200\/GO.23.00478","article-title":"Longitudinal costs of image-guided intensity-modulated radiation therapy versus three-dimensional conformal radiation: lessons from phase III PARCER trial for shaping resource-stratified guidelines in low- and middle-income countries","volume":"10","author":"Hande","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0260","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canrad.2024.10.002_bib0265","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2024.10.002_bib0270","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3802\/jgo.2023.34.e85","article-title":"FIGO staging of endometrial cancer: 2023","volume":"34","author":"Berek","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0275","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1200\/JCO.23.00062","article-title":"Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer","volume":"41","author":"Horeweg","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0280","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: a multicentre randomised trial","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.10.002_bib0285","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.10.002_bib0290","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0295","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2023.11.012","article-title":"Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel vs. sandwich therapy of carboplatin and paclitaxel followed by irradiation for advanced endometrial carcinoma","volume":"180","author":"Barlin","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0300","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.10.002_bib0305","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12885-022-10482-x","article-title":"Recurrence and survival of patients with stage III endometrial cancer after radical surgery followed by adjuvant chemo- or chemoradiotherapy: a systematic review and meta-analysis","volume":"23","author":"Cao","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2024.10.002_bib0310","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.10.002_bib0315","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","article-title":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomized, double-blind, phase 3 study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","volume":"35","author":"Van Gorp","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0320","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.brachy.2023.07.004","article-title":"Reirradiation with advanced brachytherapy techniques in recurrent GYN cancers","volume":"22","author":"Mahantshetty","year":"2023","journal-title":"Brachytherapy"},{"key":"10.1016\/j.canrad.2024.10.002_bib352","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.canrad.2022.06.016","article-title":"Reirradiation: A complex situation","volume":"26","author":"Chargari","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2024.10.002_bib0325","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1200\/JCO.23.01279","article-title":"Radiation therapy with or without cisplatin for local recurrences of endometrial cancer: results from an NRG Oncology\/GOG prospective randomized multicenter clinical trial","volume":"42","author":"Klopp","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0330","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canrad.2024.10.002_bib0335","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.23.01187","article-title":"Vulvar carcinoma: standard of care and perspectives","volume":"42","author":"Chargari","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.10.002_bib0340","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/ijgc-2023-004695","article-title":"ESTRO\/ESGO\/SIOPe guidelines for the management of patients with vaginal cancer","volume":"33","author":"Nout","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.canrad.2024.10.002_bib0345","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/ijgc-2023-004486","article-title":"European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer\u00a0\u2013\u00a0Update 2023","volume":"33","author":"Oonk","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.canrad.2024.10.002_bib0350","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1200\/JCO.23.02235","article-title":"Phase II trial of cisplatin, gemcitabine, and intensity-modulated radiation therapy for locally advanced vulvar squamous cell carcinoma","volume":"42","author":"Horowitz","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824002026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824002026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:16:56Z","timestamp":1733055416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321824002026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1278321824002026"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2024.10.002","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transformative clinical trials in gynaecologic radiation oncology in 2023\u20132024: Shaping modern treatment practices","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2024.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}